TLX News: TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM - 18th Oct 2022, 9:43am

[annb0t]

OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. PERTINENCE Early Phase I feasibility study of TLX250-CDx in patients with non-muscle-invasive bladder cancer, a collaboration with ATONCO – early results support translation to first-in-human therapeutic studies with the alpha-emitting radioisotop...

>>> Read more: TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM